These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10446177)

  • 1. Transferrin trojan horses as a rational approach for the biological delivery of therapeutic peptide domains.
    Ali SA; Joao HC; Hammerschmid F; Eder J; Steinkasserer A
    J Biol Chem; 1999 Aug; 274(34):24066-73. PubMed ID: 10446177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An antigenic HIV-1 peptide sequence engineered into the surface structure of transferrin does not elicit an antibody response.
    Ali SA; Joao HC; Hammerschmid F; Eder J; Steinkasserer A
    FEBS Lett; 1999 Oct; 459(2):230-2. PubMed ID: 10518025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB
    J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome.
    Frater J; Dunn D; Weber JN; McClure MO
    J Infect Dis; 2002 May; 185(9):1376; author reply 1376-7. PubMed ID: 12001062
    [No Abstract]   [Full Text] [Related]  

  • 6. Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
    Grant SK; Deckman IC; Minnich MD; Culp J; Franklin S; Dreyer GB; Tomaszek TA; Debouck C; Meek TD
    Biochemistry; 1991 Aug; 30(34):8424-34. PubMed ID: 1883829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional consequences of binding site mutations in transferrin: crystal structures of the Asp63Glu and Arg124Ala mutants of the N-lobe of human transferrin.
    Baker HM; He QY; Briggs SK; Mason AB; Baker EN
    Biochemistry; 2003 Jun; 42(23):7084-9. PubMed ID: 12795604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures and iron release properties of mutants (K206A and K296A) that abolish the dilysine interaction in the N-lobe of human transferrin.
    Nurizzo D; Baker HM; He QY; MacGillivray RT; Mason AB; Woodworth RC; Baker EN
    Biochemistry; 2001 Feb; 40(6):1616-23. PubMed ID: 11327820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
    Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
    J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy.
    Mayer KH; Boswell S; Goldstein R; Lo W; Xu C; Tucker L; DePasquale MP; D'Aquila R; Anderson DJ
    Clin Infect Dis; 1999 Jun; 28(6):1252-9. PubMed ID: 10451162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
    Wu X; Liu H; Xiao H; Conway JA; Kappes JC
    J Virol; 1996 Jun; 70(6):3378-84. PubMed ID: 8648668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of transferrin-binding domains in TbpB expressed by Neisseria gonorrhoeae.
    DeRocco AJ; Cornelissen CN
    Infect Immun; 2007 Jul; 75(7):3220-32. PubMed ID: 17438025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.
    Yoshimura K; Kato R; Kavlick MF; Nguyen A; Maroun V; Maeda K; Hussain KA; Ghosh AK; Gulnik SV; Erickson JW; Mitsuya H
    J Virol; 2002 Feb; 76(3):1349-58. PubMed ID: 11773409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
    Otto MJ; Garber S; Winslow DL; Reid CD; Aldrich P; Jadhav PK; Patterson CE; Hodge CN; Cheng YS
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7543-7. PubMed ID: 8356053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.
    Hoog SS; Zhao B; Winborne E; Fisher S; Green DW; DesJarlais RL; Newlander KA; Callahan JF; Moore ML; Huffman WF
    J Med Chem; 1995 Aug; 38(17):3246-52. PubMed ID: 7650677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
    Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
    Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H; Freire E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.